SAFE Fertility Group Marks 20 Years Driving Innovation in Regional IVF Market
SAFE Fertility Group celebrates 20 years of leading IVF innovation, international accreditation, and personalized reproductive care across Thailand and ASEAN.
- Celebrating its 20th anniversary, SAFE Fertility Group pioneered regional standards by becoming the first clinic in Thailand to earn RTAC certification, setting new benchmarks for the industry.
- The group drives innovation through its in-house laboratory, NGG Thailand, which uses advanced PGTseq technology for high-resolution chromosomal screening to improve pregnancy success rates.
- With a network of five locations, SAFE is capitalizing on the growing regional market by attracting international medical tourists, particularly from China, India, and ASEAN countries.
SAFE Fertility Group PCL (SAFE) is celebrating its 20th anniversary, consolidating its standing as a regional pioneer in assisted reproductive technology (ART).
Since its founding by CEO Dr. Wiwat Quangkananurug, the group has grown from a single facility into a nationwide network with five strategic locations across Thailand: Gaysorn Amarin (Headquarters), Ramindra, Sriracha, Khon Kaen, and Phuket.
SAFE established a key national milestone by becoming the first clinic in Thailand to earn Reproductive Technology Accreditation Committee (RTAC) certification from Australia and New Zealand.
This achievement helped standardize reproductive laboratory protocols and patient safety benchmarks across the country's healthcare sector.
To maintain precision and quality control, SAFE operates its own dedicated embryology laboratory subsidiary, NGG Thailand.
The lab utilizes PGTseq technology combining Targeted Next-Generation Sequencing (NGS) with Single Nucleotide Polymorphisms (SNP) analysis to achieve 3-Mb resolution embryo chromosomal screening.
This advanced diagnostic infrastructure improves pregnancy success rates, detects genetic abnormalities such as Down syndrome early, and serves external hospital partners throughout the region.
The expansion aligns with shifting global demographics, including delayed parenthood and declining Total Fertility Rates (TFR) worldwide.
As couples prioritize career stability before starting families, advanced ICSI and IVF procedures have evolved from basic infertility treatments into essential tools for ensuring embryo quality and safe pregnancies.
Despite broader demographic headwinds, Thailand’s fertility treatment sector continues to expand at 5–6% annually, targeting an estimated THB 6.3 billion valuation. Driven by rising average spending per case and robust medical tourism particularly from Chinese, Indian, and ASEAN patients
SAFE leverages its multilingual personal assistant model and split-cycle international protocols to capture high-value market demand.
